Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands
Elaine C. Petronilho(Universidade Federal do Rio de Janeiro), Jerson L. Silva(National Institute of Science and Technology for Structural Biology and Bioimaging), Murilo M. Pedrote(Universidade Federal do Rio de Janeiro), Adriani L. Felix(Universidade Federal do Rio de Janeiro), Benjamin Jakobus(Universidade do Estado do Rio de Janeiro), Giulia D. S. Ferretti(Medical University of South Carolina), Yraima Cordeiro(Universidade Federal do Rio de Janeiro), Fernando P. Almeida(Universidade Federal do Rio de Janeiro), Filipe Pereira da Costa(Universidade Federal do Rio de Janeiro), Mayra A. Marques(Universidade Federal do Rio de Janeiro), Gileno dos S. de Sousa(Universidade Federal do Rio de Janeiro), Michelle F. Mota(Universidade Federal do Rio de Janeiro), Tuane C. R. G. Vieira(Universidade Federal do Rio de Janeiro), Yulli M. Passos(Universidade Federal do Rio de Janeiro), Guilherme A. P. de Oliveira(Universidade Federal do Rio de Janeiro)
Cited by 108
Related Papers
Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor Proteins
|Accounts of Chemical Research|2009|110
p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
|Journal of Biological Chemistry|2019|86
Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers
|iScience|2020|82
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
|Chemical Reviews|2023|78
Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues
|Molecules|2020|66